Anidulafungin
An echinocandin that beat fluconazole for invasive candidiasis
Anidulafungin is a semi-synthetic cyclic lipopeptide echinocandin that blocks the fungal cell-wall enzyme beta-(1,3)-D-glucan synthase. Approved as Eraxis in 2006, it is given by daily intravenous infusion for candidaemia and esophageal candidiasis, and it is broken down chemically in the blood rather than by the liver.
Manufacturer's recommended dosing (FDA label): 200 mg loading dose, then 100 mg, Once daily, Intravenous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Anidulafungin is an echinocandin, a cyclic lipopeptide antifungal that blocks the enzyme Candida needs to build its cell wall. Unusually for a drug, it is not metabolised by the liver: it degrades slowly by itself in blood to an inactive ring-opened peptide, which avoids many liver-related drug interactions. Its terminal half-life is 40 to 50 hours, which is why a double loading dose on day one gets it to steady state quickly.
In a 2007 trial in 245 patients with invasive candidiasis, mostly candidaemia, treatment succeeded in 75.6% on anidulafungin against 60.2% on fluconazole, a 15.4-point difference. In 601 patients with esophageal candidiasis it matched oral fluconazole, with endoscopic success of 97.2% against 98.8%. A short intravenous course followed by an early switch to an oral azole worked in 83.7% of 250 patients.
Intensive care is where dosing is questioned. In 20 critically ill patients, standard doses reached the pharmacokinetic target in only about half, with heavier patients and those with low albumin at the most risk; yet in 146 critically ill patients with candidaemia, obese patients were cured as often as others.
It has been tested against the hardest Candida too. In 154 Turkish patients with Candida auris bloodstream infection, a multidrug-resistant species, matched groups on anidulafungin and micafungin had identical 30-day mortality (41.8%) and similar clearance, and no echinocandin resistance was found. In an Indian intensive-care series it performed about like caspofungin overall.
As prophylaxis after high-risk liver transplantation, a double-blind trial found it as effective as fluconazole overall, with a trend toward less Aspergillus colonisation or infection (3% against 9%). In leukaemia induction, though, a propensity-matched analysis found no fewer fungal infections with anidulafungin prophylaxis than without.
FDA approved it as Eraxis on February 17, 2006; the label now covers children from 1 month for candidaemia, and a study in infants under 2 found adult-like exposure. Warnings cover liver reactions, anaphylaxis and hypersensitivity, polysorbate toxicity in newborns, and hereditary fructose intolerance. It is given only intravenously, no faster than 1.1 mg per minute.
Mechanism of Action
Anidulafungin blocks fungal cell-wall synthesis and breaks down on its own in the blood rather than in the liver.
Glucan synthase
Inhibits 1,3-beta-D-glucan synthase, stopping Candida from building its cell wall.
Self-degrading
Slowly degrades chemically in blood to an inactive peptide rather than being metabolised by the liver (label 12.3).
Long-lived
Terminal half-life 40 to 50 hours; a loading dose of twice the daily dose is given on day one (label).
Published Research
The trials behind anidulafungin, from their PubMed abstracts.
Against fluconazole for invasive candidiasis
In 245 patients, 89% with candidaemia only, treatment success at the end of intravenous therapy was 75.6% on anidulafungin against 60.2% on fluconazole (difference 15.4 points, 95% CI 3.9 to 27.0).
Esophageal candidiasis
In 601 patients, endoscopic success was 97.2% on intravenous anidulafungin and 98.8% on oral fluconazole, meeting noninferiority; treatment-related adverse events were 9.3% against 12.0%.
Children aged 2 to 17
In an open-label study of 49 children with invasive candidiasis, all had at least one treatment-emergent adverse event (most often vomiting, diarrhoea and fever), 4 stopped for drug-related events, and all-cause mortality was 14.3% by week 6.
Prophylaxis after liver transplant: against fluconazole
Overall efficacy was similar to fluconazole; anidulafungin was associated with less Aspergillus colonisation or infection (3% against 9%) and no antifungal resistance, with similar rejection, fungal-free survival and mortality.
Early step-down to oral azoles
In 250 patients with candidaemia or invasive candidiasis, a short course of intravenous anidulafungin followed by early switch to an oral azole achieved 83.7% global response at end of treatment, similar across Candida species.
Infants under 2
In 19 infants aged 1 month to 2 years, 3 mg/kg then 1.5 mg/kg daily gave adult-like exposure and 68.8% global response at the end of intravenous therapy, with no treatment-related deaths.
Exposure in critically ill patients
In 20 critically ill patients with invasive candidiasis, standard dosing reached the pharmacokinetic target in only 45% early and 65% late in treatment; clearance rose with body weight and low albumin changed distribution.
Obesity and candidaemia outcomes
In 146 critically ill patients with candidaemia, 64 of them obese, clinical and microbiological cure on standard anidulafungin doses did not differ by obesity.
Prophylaxis during leukaemia induction
In a propensity-matched analysis of patients starting treatment for acute myeloid leukaemia, anidulafungin prophylaxis was not associated with fewer invasive fungal infections than no prophylaxis; low neutrophil counts were the main risk factor.
Candida auris candidaemia
In 55 propensity-matched pairs with Candida auris candidaemia, 30-day mortality was 41.8% on both anidulafungin and micafungin, with similar microbiological response (90.9% against 94.5%) and relapse; no echinocandin resistance was detected.
Intensive care in India
In 62 intensive-care patients with invasive Candida infection, global response was 46.5% on anidulafungin and 47.1% on caspofungin; it was an observational comparison of unequal groups.
Dosing Data
Eraxis is infused intravenously once daily after a loading dose, at no more than 1.1 mg per minute; the course runs at least 14 days after the last positive culture for candidaemia.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Eraxis (anidulafungin injection): For injection: 50 mg, and 100 mg as a lyophilized powder in a single-dose vial for reconstitution. Forms the label lists: single-dose vials.
Source: Eraxis (anidulafungin injection) label, section 3 (DailyMed version 24, effective August 19, 2025).
Mixing a vial: a worked example
The approved product Eraxis (anidulafungin injection) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “Reconstitution of the 50 mg/vial Aseptically reconstitute each 50 mg vial with 15 mL of sterile Water for Injection to provide a concentration of 3.33 mg/mL.”
Source: Eraxis (anidulafungin injection) label, sections 2 and 3 (DailyMed version 24, effective August 19, 2025).
Storage before and after mixing
Before mixing or first use: “Infusion Solution ERAXIS infusion solution can be stored at temperatures up to 25°C (77°F) for up to 48 hours.” “Storage of the Reconstituted Solution ERAXIS reconstituted solution can be stored at 25°C (77°F) for up to 24 hours prior to dilution into the infusion solution.” “Do not freeze.”
After mixing or first use: “ERAXIS vials ERAXIS (unreconstituted) vials should be stored in a refrigerator at 2°C – 8°C (36°F – 46°F).” “Reconstituted solution ERAXIS reconstituted solution can be stored at up to 25°C (77°F) for up to 24 hours.” “From a microbiological point of view, following good aseptic practices, the reconstituted solution can be utilized for up to 24 hours when stored at 25°C.”
The label also sets storage out in a table that does not read well out of context: see section 16 of the label linked below.
Source: Eraxis (anidulafungin injection) label, sections 16 and 2 (DailyMed version 24, effective August 19, 2025).
How it is taken
As the approved label gives it: Intravenous (Once daily; Label: candidaemia and other Candida infections, adults).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of terminal half-life 40 to 50 hours. After about five half-lives almost none is left.
How long the doses were given: Label: candidaemia and other Candida infections, adults: At least 14 days after the last positive culture; Label: oesophageal candidiasis, adults: At least 14 days, and 7 days after symptoms resolve; Label: candidaemia, children 1 month and older: At least 14 days after the last positive culture.
When effects appear: unknown; no source on this page gives a time to effect for Anidulafungin. Results reported in the studies are under Published Research.
Source: half-life: Eraxis prescribing information, section 12.3 (DailyMed set a88d9010, effective August 19, 2025); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Treatment-related adverse events in 9.3% against 12.0% on fluconazole in the esophageal trial. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Anidulafungin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- cyclosporine, voriconazole, tacrolimus: no significant change in either drug; no dose adjustment
- rifampin, liposomal amphotericin B: no significant change in anidulafungin; no dose adjustment
Every peptide's record, with its source: the interaction matrix.
Source: Pfizer. ERAXIS (anidulafungin) US prescribing information, section 7. DailyMed version of August 19, 2025, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Anidulafungin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Eraxis, NDA 021632, on February 17, 2006 (Drugs@FDA via openFDA and the Eraxis label effective August 19, 2025, read October 3, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Eraxis label (DailyMed, effective August 19, 2025).
Legal Status
Anidulafungin is an approved prescription drug in the US.
Frequently Asked Questions
?Is anidulafungin a peptide?
Yes. It is a cyclic lipopeptide echinocandin, a ring of amino acids with a fatty side chain.
?How is anidulafungin different from other echinocandins?
It is not broken down by the liver; it degrades chemically in blood. Rezafungin, a newer echinocandin, is a structural analogue designed to last long enough for weekly dosing.
?Was anidulafungin better than fluconazole?
In a 2007 trial of invasive candidiasis, treatment success was 75.6% on anidulafungin against 60.2% on fluconazole.
?Can anidulafungin be taken by mouth?
No. Echinocandins are not absorbed from the gut, so anidulafungin is given only by intravenous infusion, with a loading dose on the first day.
?Is anidulafungin approved for children?
Yes, for candidaemia and other Candida infections in children 1 month and older. In an open-label study of 49 children aged 2 to 17, all had at least one adverse event, most often vomiting, diarrhoea and fever, and 4 stopped because of drug-related events.
?How long is anidulafungin given for?
For candidaemia and other Candida infections, the label says to continue for at least 14 days after the last positive culture, after a loading dose on day 1. Esophageal candidiasis is treated for at least 14 days and for at least 7 days after symptoms resolve.
References
- [fda] US FDA, Drugs@FDA (openFDA): ERAXIS, NDA 021632 (February 17, 2006). Read October 3, 2026.
- [fda-pi] FDA. Eraxis (anidulafungin) US prescribing information (DailyMed set a88d9010-55fb-4a02-baff-042cd27688ea, version 24, effective August 19, 2025). Read October 3, 2026.
- [pubmed] Reboli AC, et al. "Anidulafungin versus fluconazole for invasive candidiasis." N Engl J Med, 2007;356(24):2472-82. PMID: 17568028.
- [pubmed] Krause DS, et al. "A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis." Clin Infect Dis, 2004;39(6):770-5. PMID: 15472806.
- [pubmed] Roilides E, et al. "A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age." Pediatr Infect Dis J, 2019;38(3):275-279. PMID: 30418357.
- [pubmed] Winston DJ, et al. "Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients." Am J Transplant, 2014;14(12):2758-64. PMID: 25376267.
- [clinical-trial] Vazquez J, et al. "Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial." BMC Infect Dis, 2014;14:97. PMID: 24559321.
- [clinical-trial] Roilides E, et al. "Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia." Pediatr Infect Dis J, 2020;39(4):305-309. PMID: 32032174.
- [pubmed] Elkayal O, et al. "Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis." Infection, 2025;53(3):1155-1165. PMID: 39641856.
- [pubmed] Alsowaida YS, et al. "Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study." Int J Infect Dis, 2024;148:107234. PMID: 39241957.
- [pubmed] Silva WFD, et al. "Assessing the impact of prophylactic anidulafungin during remission induction of acute myeloid leukemia - A propensity-score matching analysis." J Mycol Med, 2023;33(4):101434. PMID: 37683564.
- [fda-pi] Eraxis (anidulafungin) for injection US prescribing information (DailyMed set a88d9010, version 24, effective August 19, 2025), sections 2.1-2.3; read through openFDA October 6, 2026.
- [pubmed] Arslan E, et al. "Clinical Outcomes of Micafungin and Anidulafungin in Candidozyma auris (Formerly Candida auris) Candidemia: A Propensity Score-Matched Retrospective Cohort Study." J Fungi (Basel), 2026;12(7). PMID: 42506298.
- [pubmed] Mehta Y, et al. "Evaluating the Efficacy and Safety of Anidulafungin and Caspofungin in Invasive Candida Infections in Intensive Care Units in India: A Prospective, Observational, Multicenter, Open-Label Study." Cureus, 2025;17(7):e88039. PMID: 40821127.
Sources & Citations
Studies were read from their PubMed abstracts; the Eraxis label from DailyMed (set a88d9010, effective August 19, 2025) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.